Curis Gets $3M From Genentech For Ovarian Cancer Trial Initiation
Luke Timmerman12/8/08
Cambridge, MA-based Curis (NASDAQ: CRIS) said today it will receive a $3 million cash payment from its partner, Genentech (NYSE: DNA). The payment is due because Genentech is starting a clinical trial among patients with ovarian cancer. Researchers will look at 100 patients with the disease, taking either a placebo or GDC-0449, an oral pill made to block the action of the Hedgehog pathway, which is thought to be critical to the survival of cancer cells and their ability to resist chemotherapy.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
